Cambrian BioPharma Inc's Form 4/A amendment
AmendedFaeth Therapeutics, Inc. (FTH) · filed Apr 21, 2022
- Accession no.
- 0001567619-22-008800
- Filed
- Apr 21, 2022
- Trade date
- Mar 23, 2021
- Filing delay
- 394 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Mar 24, 2021
This filing lists 1 non-derivative transaction. Open-market purchases total $136.2K. It was filed 394 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cambrian BioPharma IncCIK 0001797409 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 23, 2021 | Common Stock | PPurchaseAcquired | +9,500 | $14.34F2 | +$136,230 | 4,798,293 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on March 24, 2021, overstated the number of shares purchased.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
Referenced by the price of 1 transaction in Table I.
- F3
These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.